EyeGate Pharma Stock Jumps On Initiation Of Proof Of Concept Trial With DHODH Inhibitor In Ophthalmology Indications
EyeGate Pharmaceuticals Inc (NASDAQ:EYEG) has dosed the patient in Phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients…